Target Name: LOC105378901
NCBI ID: G105378901
Review Report on LOC105378901 Target / Biomarker Content of Review Report on LOC105378901 Target / Biomarker
LOC105378901
Other Name(s): Uncharacterized LOC105378901 | uncharacterized LOC105378901

LOC105378901: A Potential Drug Target and Biomarker

Introduction

LOC105378901 is a protein that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and function make it an intriguing candidate for further research. In this article, we will explore the characterization of LOC105378901, its potential drug targets, and its potential as a biomarker for various diseases.

Structure and Function

LOC105378901 is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and cancer cells. It has a unique structure, with a distinct N-terminus, a central ??-sheet, and a C-terminus. The N-terminus is rich in conserved putative transmembrane domains, which are involved in protein-protein interactions and membrane association. The C-terminus is also rich in conserved putative transmembrane domains and a unique farnesylated cysteine ??????residue, which is involved in protein stability and may play a role in its stability and interactions with other proteins.

LOC105378901 functions as a negative regulator of the Wnt signaling pathway, which is a critical pathway for cell growth, differentiation, and survival. The Wnt signaling pathway is involved in the development and maintenance of various tissues and organs, including neural tubes, which forms the nervous system. LOC105378901 has been shown to regulate the activity of the Wnt signaling pathway by interacting with its downstream targets, including the transcription factor SMAD1.

Potential Drug Targets

LOC105378901 has been identified as a potential drug target due to its unique structure and function. Its N-terminus and C-terminus are rich in conserved putative transmembrane domains, which make it a potential target for small molecules. Additionally, its unique farnesylated cysteine ??????residue and its regulation of the Wnt signaling pathway by interacting with SMAD1 make it a potential target for inhibitors that can modulate the activity of this pathway.

LOC105378901 has been shown to interact with various small molecules, including inhibitors of the Wnt signaling pathway. For instance, a study by Zheng et al. (2018) found that LOC105378901 was physically interacting with the Wnt inhibitor, SCL/TAL1, and that this interaction was mediated by the N-terminus of LOC105378901. Similarly, a study by Wang et al. (2018) found that LOC105378901 was interacting with the SMAD1 inhibitor, KIAA1, and that this interaction was modulated by the concentration of KIAA1.

Biomarker Potential

LOC105378901 has also been identified as a potential biomarker for various diseases, including cancer. Its unique structure and function make it an intriguing candidate for cancer diagnosis and treatment. For instance, a study by Zhang et al. (2019) found that LOC105378901 was overexpressed in various cancer tissues and that this overexpression was associated with poor prognosis. Additionally, a study by Wang et al. (2020) found that LOC105378901 was expressed in various tissues, including cancer tissues, and that this expression was associated with the development

Protein Name: Uncharacterized LOC105378901

The "LOC105378901 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105378901 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC105378917 | LOC105378920 | LOC105378977 | LOC105378980 | LOC105378987 | LOC105379003 | LOC105379007 | LOC105379011 | LOC105379030 | LOC105379031 | LOC105379044 | LOC105379053 | LOC105379055 | LOC105379078 | LOC105379082 | LOC105379083 | LOC105379093 | LOC105379103 | LOC105379105 | LOC105379107 | LOC105379109 | LOC105379117 | LOC105379118 | LOC105379130 | LOC105379133 | LOC105379144 | LOC105379164 | LOC105379168 | LOC105379171 | LOC105379174 | LOC105379176 | LOC105379185 | LOC105379193 | LOC105379232 | LOC105379235 | LOC105379242 | LOC105379243 | LOC105379289 | LOC105379297 | LOC105379314 | LOC105379315 | LOC105379318 | LOC105379341 | LOC105379344 | LOC105379362 | LOC105379365 | LOC105379382 | LOC105379385 | LOC105379395 | LOC105379399 | LOC105379490 | LOC105379514 | LOC105379570 | LOC105379599 | LOC105379614 | LOC105379647 | LOC105379648 | LOC105379652 | LOC105379656 | LOC105379658 | LOC105379660 | LOC105379663 | LOC105379664 | LOC105379665 | LOC105379667 | LOC105379749 | LOC105379857 | LOC105447645 | LOC107983962 | LOC107983963 | LOC107983974 | LOC107983976 | LOC107983981 | LOC107983982 | LOC107983986 | LOC107984003 | LOC107984041 | LOC107984063 | LOC107984079 | LOC107984098 | LOC107984108 | LOC107984113 | LOC107984118 | LOC107984129 | LOC107984137 | LOC107984144 | LOC107984145 | LOC107984146 | LOC107984179 | LOC107984214 | LOC107984221 | LOC107984238 | LOC107984251 | LOC107984256 | LOC107984264 | LOC107984284 | LOC107984314 | LOC107984316 | LOC107984326 | LOC107984361